• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    10/2/23 5:31:38 PM ET
    $ACXP
    $ALXO
    $CNTB
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACXP alert in real time by email

    Gainers

    • MSP Recovery (NASDAQ:LIFW) shares rose 18.9% to $0.24 during Monday's after-market session. At the close, MSP Recovery's trading volume reached 7.7 million shares. This is 22.5% of its average volume over the last 100 days. The market value of their outstanding shares is at $78.8 million.
    • ALX Oncology Holdings (NASDAQ:ALXO) stock rose 17.46% to $5.65. Trading volume for this security closed at 50.4K, accounting for 31.9% of its average full-day volume over the last 100 days. The company's market cap stands at $232.5 million.
    • SenesTech (NASDAQ:SNES) shares moved upwards by 10.51% to $0.47. The company's market cap stands at $1.3 million.
    • China Pharma Holding (AMEX:CPHI) stock rose 8.81% to $0.15. The company's market cap stands at $1.7 million.
    • Phio Pharma (NASDAQ:PHIO) shares moved upwards by 7.89% to $1.64. The market value of their outstanding shares is at $3.6 million.
    • GRI Bio (NASDAQ:GRI) stock moved upwards by 7.87% to $1.78. The company's market cap stands at $5.2 million.

    Losers

    • Impel Pharmaceuticals (NASDAQ:IMPL) stock decreased by 8.9% to $0.38 during Monday's after-market session. The company's market cap stands at $8.9 million.
    • Acurx Pharmaceuticals (NASDAQ:ACXP) stock decreased by 7.81% to $1.3. This security traded at a volume of 5.9 million shares come close, making up 16927.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $16.9 million.
    • Connect Biopharma Hldgs (NASDAQ:CNTB) stock fell 7.44% to $0.93. The market value of their outstanding shares is at $50.9 million.
    • SmileDirectClub (NASDAQ:SDC) shares decreased by 6.96% to $0.15. Trading volume for this security closed at 6.4 million, accounting for 292.9% of its average full-day volume over the last 100 days. The company's market cap stands at $20.0 million.
    • Redhill Biopharma (NASDAQ:RDHL) stock decreased by 6.59% to $0.43. The company's market cap stands at $2.4 million.
    • Takeda Pharmaceutical (NYSE:TAK) stock decreased by 5.83% to $14.39. The market value of their outstanding shares is at $44.7 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACXP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP
    $ALXO
    $CNTB
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    ALX Oncology Holdings Inc.
    $ALXO
    3/19/2026$5.00Overweight
    Wells Fargo
    ALX Oncology Holdings Inc.
    $ALXO
    3/6/2026$6.00Buy
    UBS
    Takeda Pharmaceutical Company Limited
    $TAK
    1/13/2026Overweight
    Morgan Stanley
    Connect Biopharma Holdings Limited
    $CNTB
    12/1/2025$9.00Buy
    Lake Street
    ALX Oncology Holdings Inc.
    $ALXO
    11/13/2025$4.00Buy
    Jefferies
    Connect Biopharma Holdings Limited
    $CNTB
    10/31/2025$10.00Buy
    BTIG Research
    Connect Biopharma Holdings Limited
    $CNTB
    6/12/2025$7.00Buy
    H.C. Wainwright
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACXP
    $ALXO
    $CNTB
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

    – Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 – – Entered into a securities purchase agreement for $20.2 million equity financing extending our cash runway into second half of 2027 – SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceuti

    3/31/26 4:05:00 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

    About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studiesA significantly greater PASI 75 response rate versus placebo was observed as early as week 4Safety profile consistent with Phase 2b studies with no new safety signals identifiedTORONTO, March 31, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) An

    3/31/26 8:00:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

    STATEN ISLAND, N.Y., March 30, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the Korean Intellectual Property Office (KIPO) has granted a new patent which covers DNA Polymerase IIIC inhibitors including compositions‑of‑matter, methods of use, and pharmaceutical compositions, which further strengthen Acurx's intellectual property portfolio and represents the most recent addition to its expanding series of granted patents in the U.S. and abroad. To date, Acurx has secured four U.S. patents, alo

    3/30/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $CNTB
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on ALX Oncology with a new price target

    Wells Fargo initiated coverage of ALX Oncology with a rating of Overweight and set a new price target of $5.00

    3/19/26 8:25:33 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on ALX Oncology with a new price target

    UBS resumed coverage of ALX Oncology with a rating of Buy and set a new price target of $6.00

    3/6/26 8:38:03 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Takeda Pharma

    Morgan Stanley resumed coverage of Takeda Pharma with a rating of Overweight

    1/13/26 8:31:07 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $CNTB
    $CPHI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $CNTB
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ACXP
    $ALXO
    $CNTB
    $CPHI
    SEC Filings

    View All

    SEC Form 10-K filed by China Pharma Holdings Inc.

    10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

    4/1/26 4:15:23 PM ET
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by China Pharma Holdings Inc.

    NT 10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

    4/1/26 4:05:03 PM ET
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Connect Biopharma Holdings Limited

    10-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    3/31/26 4:10:38 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $CNTB
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Xanthopoulos Kleanthis Gabriel

    4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    4/2/26 4:27:54 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Liu Jean I

    4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    4/2/26 4:25:01 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Huang James

    4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    4/1/26 4:30:16 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $CNTB
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    Alan Walshe Appointed General Manager of Takeda Canada

    A proven people‑focused commercial strategist with extensive global experience to lead Takeda Canada's next chapter of growth and impact.TORONTO, March 2, 2026  /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Alan Walshe as General Manager for Canada. Alan brings 17 years of experience with Takeda and its predecessor companies, most recently serving as Global Head of Commercial Strategy for the Plasma‑Derived Therapies Business Unit."Alan's depth of commercial expertise and global perspective, combined with his people‑focused leadership sty

    3/2/26 7:59:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $CNTB
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 7:22:54 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $CNTB
    $CPHI
    Financials

    Live finance-specific insights

    View All

    Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

    – Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting –  – Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET – SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today anno

    3/30/26 7:01:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

    – Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing – – The rapid improvement in FEV1 demonstrated with IV rademikibart in this study provides clinical confirmation of preclinical observations that rademikibart has a unique beneficial effect on bronchodilation – – Mean FEV1 improvements of ~200 - 400 mL were maintained through Day 29 in asthma and COPD patients – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD;

    3/30/26 7:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

    About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda ((TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that conven

    3/28/26 3:00:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care